Telix Pharmaceuticals Ltd Ordinary Shares TLX
News
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
Telix Announces Reorganisation to Deliver on Strategic Priorities
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals